Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Avera McKennan Hospital & University Health Center
A total of 30 subjects will be enrolled in this study. They will be randomized in to one of two groups. One group (of 20 subjects) will take 500 mg of the investigational product (IHBG-10) 15 minutes prior to the three main meals of the day; subjects will continue to take their prescribed anti-psychotic medications. The other group (of 10 subjects) will take a placebo 15 minutes prior to the three main meals of the day; subjects will continue to take their prescribed anti-psychotic medications. Subjects will take the investigational product or placebo for 12 weeks. Participation in this study involves 4 study visits.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men and women, age 18 and older
Agree to keep diet, exercise and all current health habits stable during participation in the study
Have been taking Risperdal (Risperidone), Seroquel (Quetiapine), or Zyprexa (Olanzapine) for less than 3 months
You may not be if
Current active acute psychotic episode
Women who are pregnant, breastfeeding or planning to become pregnant
Prior bariatric surgery
Use of prescription or over-the-counter appetite suppressants, herbal products or other medications for weight loss within the past month
Obesity as a result of a clinically-diagnosed endocrine problem
Clareo Health | Anti-psychotic Medication (New Use) Weight Loss Study
